Navigation Links
ZD1839 Proves Effective - A Breakthrough in fighting Lung Cancer

Lung cancer, the header among all forms of cancer, is avenged now by the new proven effective ZD1839.

It has been shown that ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, has confirmed, durable responses and safety in patients with advanced non-small cell lung cancer (NSCLC) as monotherapy and in combination with standard chemotherapy agents after segmental scrutinization in two different studies.

Vincent Miller, MD, of Memorial Sloan-Kettering Cancer Center in New York and the principal investigator of the first study said, "It is hoped that our study will be a prelude to better outcomes for NSCLC patients in the near future." No novel toxicities were seen with ZD1839 treatment in combination with standard chemotherapy.

In a second study, which addressed intermittent dosing of ZD1839 in Japanese patients with advanced lung cancer, more than 20% of patients showed partial responses to ZD1839 between 1 and 11 months.

With such promising results, researchers are now working on whether this drug can be used for other forms of cancer as well.
'"/>




Page: 1

Related medicine news :

1. Study Proves That MMR Vaccine Is Not Connected To Autistic Babies
2. Pilot Study Proves Home Abortions ‘Safe’
3. Many Nonprescription Cough Medicines Proves Ineffective
4. Less Invasive By Pass Surgery Proves Economical In The Long Run
5. Epidural Mistakes Proves To Be Fatal Blunders
6. Combined Anti-Fever Drug Therapy Proves Unsafe for Childhood Fever
7. Drug Trial Proves Nightmare for British Indian Student
8. Naturopathic Care Proves Beneficial for TMD Pain
9. Medtronic Device Proves Effective in Parkinson’s Diseas
10. Large Community Spirometry Screening Proves Successful
11. Pregabalin Proves Durable Pain Relief Option for Fibromyalgia
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. ... The attorneys chosen by their peers for this recognition are considered among the top ... Shareholders received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented ... in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... One of Australia,s successful biotechnology ... a new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ... to list on the ASX. Noxopharm is a clinic-ready ... a Phase 1 clinical study later this year. ... the biggest problems facing cancer patients - the ability of cancers ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
Breaking Medicine Technology: